- Home
- OPRX vs FATE Comparison
OPRX vs FATE Comparison
Compare OPRX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- FATE
- Stock Information
- Founded
- OPRX 2006
- FATE 2007
- Country
- OPRX United States
- FATE United States
- Employees
- OPRX N/A
- FATE N/A
- Industry
- OPRX Business Services
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPRX Consumer Discretionary
- FATE Health Care
- Exchange
- OPRX Nasdaq
- FATE Nasdaq
- Market Cap
- OPRX 154.9M
- FATE 177.7M
- IPO Year
- OPRX N/A
- FATE 2013
- Fundamental
- Price
- OPRX $12.64
- FATE $1.14
- Analyst Decision
- OPRX Buy
- FATE Hold
- Analyst Count
- OPRX 8
- FATE 7
- Target Price
- OPRX $10.81
- FATE $3.83
- AVG Volume (30 Days)
- OPRX 227.5K
- FATE 1.9M
- Earning Date
- OPRX 08-07-2025
- FATE 08-12-2025
- Dividend Yield
- OPRX N/A
- FATE N/A
- EPS Growth
- OPRX N/A
- FATE N/A
- EPS
- OPRX N/A
- FATE N/A
- Revenue
- OPRX $94,365,000.00
- FATE $13,335,000.00
- Revenue This Year
- OPRX $14.44
- FATE N/A
- Revenue Next Year
- OPRX $10.63
- FATE N/A
- P/E Ratio
- OPRX N/A
- FATE N/A
- Revenue Growth
- OPRX 20.66
- FATE 105.85
- 52 Week Low
- OPRX $3.78
- FATE $0.66
- 52 Week High
- OPRX $15.71
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- OPRX 44.61
- FATE 46.69
- Support Level
- OPRX $12.88
- FATE $1.05
- Resistance Level
- OPRX $13.95
- FATE $1.18
- Average True Range (ATR)
- OPRX 0.73
- FATE 0.08
- MACD
- OPRX -0.16
- FATE -0.00
- Stochastic Oscillator
- OPRX 16.67
- FATE 54.76
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.